A team of CiRA researchers has uncovered the crucial role of EIF3D—a protein translational regulator—in primed pluripotency. The research is published in the journal Science Advances.

Sanofi’s technology for making natural killer (NK) cell therapies came from an M&A move. The pharmaceutical giant just struck a deal that adds a CRISPR-editing technology to its to toolkit for ...

Sanofi and Scribe Therapeutics will partner to develop CRISPR-based cell therapies to fight cancer, the companies said today. The collaboration could generate more than $1 billion for the CRISPR ...

A fertilized egg somehow manages to build skin, brain, and blood cells within days. But how? New tech called LoxCode is ...

CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for ...

Double-edited NK cells have superior anti-tumor activity A) Percentage of FLAG-positive NK cells measured 7 days post CRISPR-Cas9 RNP electroporation and AAV transduction.

Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story By Nick Paul Taylor Sep 27, 2022 8:15am Scribe Therapeutics Sanofi CRISPR Cell & Gene Therapy ...

Using CRISPR-Cas9, scientists can make precise changes to the genome during brain development, and then closely study how those changes affect individual cells using single-cell transcriptomic ...

Solid tumors often present formidable barriers for T cells to overcome, and the sheer volume of cancer cells can lead to T-cell exhaustion, rendering them ineffective. To address this need, the ...

Sickle cell disease, long ignored by drugmakers, turned out to be a perfect target for the flashy gene editing tool CRISPR. The question is, what next?